Home / Market News / $GENB

$GENB news and market catalysts

The 7 most recent market catalysts affecting $GENB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 3 high impact 4 bullish 1 bearish Biotechnology
Nov 12, 2026 Corporate Catalyst Bearish Impact 92
Generate Biomedicines Reports Third Quarter 2026 Financial Results
Generate Biomedicines reported a net loss of $87.657 million, a substantial increase from $65.207 million in Q3 2025. Concurrently, revenue plummeted by 56.2% to $4.220 million. Th…
Oct 14, 2026 Corporate Catalyst Bullish Impact 85
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Generate Biomedicines (GENB) has entered a strategic collaboration with Zealand Pharma to develop AI-engineered protein therapies for obesity and metabolic diseases. This is a sign…
Oct 13, 2026 Corporate Catalyst Bullish Impact 75
Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration
Generate Biomedicines (GENB) has secured a significant collaboration with Zealand Pharma (ZEAL), involving an upfront payment of $30 million and potential milestones up to $1.2 bil…
Oct 5, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reaffirmed a 'Buy' rating and a $30 price target for Generate Biomedicines. This action signals that the analyst's positive outlo…
Sep 8, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterated a 'Buy' rating and a $30 price target for Generate Biomedicines (GENB). This action signals that the analyst firm maintain…
Aug 28, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Generate Biomedicines, Raises Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on Generate Biomedicines (GENB) and raised the price target from $25 to $30. This action signals contin…
Aug 6, 2026 Corporate Catalyst Bullish Impact 85
Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate
Generate Biomedicines (GENB) released its Q2 earnings, showing a mixed performance. While the company managed to beat EPS estimates, reporting a loss of $(0.52) against an expected…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.